Alivus Life Sciences (NSE:ALIVUS) Beneish M-Score: -2.18 (As of Jun. 26, 2026)


NSE:ALIVUS Alivus Life Sciences Ltd NSE:ALIVUS
83 GF Score
Price ₹1,108.30
GF Value ₹1,004.54
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Alivus Life Sciences Beneish M-Score?

Alivus Life Sciences NSE:ALIVUS -0.70% 83 Beneish M-Score is -2.18 as of Jun. 26, 2026. GuruFocus rates NSE:ALIVUS with a GF Score™ of 83/100 and a GF Value™ of ₹1,004.54 (Fairly Valued). The stock has 3 warning signs investors should review. Among 911 Drug Manufacturers companies, Alivus Life Sciences ranks worse than 71.35% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.18 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Alivus Life Sciences's Beneish M-Score or its related term are showing as below:

NSE:ALIVUS' s Beneish M-Score Range Over the Past 10 Years
Min: -2.58   Med: -2.35   Max: -1.84
Current: -2.18

During the past 8 years, the highest Beneish M-Score of Alivus Life Sciences was -1.84. The lowest was -2.58. And the median was -2.35.


Alivus Life Sciences Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Alivus Life Sciences's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alivus Life Sciences Beneish M-Score Chart

Alivus Life Sciences Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial -2.58 -1.84 -2.39 -2.30 -2.18

Alivus Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.30 0.00 0.00 0.00 -2.18

NSE:ALIVUS vs ZTS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Alivus Life Sciences's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alivus Life Sciences Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alivus Life Sciences's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Alivus Life Sciences's Beneish M-Score falls into.


NSE:ALIVUS
83GF Score
Alivus Life Sciences Ltd NSE:ALIVUS
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alivus Life Sciences Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Alivus Life Sciences for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9941+0.528 * 0.9401+0.404 * 1.1811+0.892 * 1.0691+0.115 * 0.9936
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0+4.679 * -0.000233-0.327 * 0.9152
=-2.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ₹10,730 Mil.
Revenue was ₹25,518 Mil.
Gross Profit was ₹14,853 Mil.
Total Current Assets was ₹26,494 Mil.
Total Assets was ₹39,829 Mil.
Property, Plant and Equipment(Net PPE) was ₹12,914 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹754 Mil.
Selling, General, & Admin. Expense(SGA) was ₹0 Mil.
Total Current Liabilities was ₹5,080 Mil.
Long-Term Debt & Capital Lease Obligation was ₹488 Mil.
Net Income was ₹5,645 Mil.
Gross Profit was ₹0 Mil.
Cash Flow from Operations was ₹5,654 Mil.
Total Receivables was ₹10,096 Mil.
Revenue was ₹23,869 Mil.
Gross Profit was ₹13,060 Mil.
Total Current Assets was ₹23,352 Mil.
Total Assets was ₹34,115 Mil.
Property, Plant and Equipment(Net PPE) was ₹10,457 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹606 Mil.
Selling, General, & Admin. Expense(SGA) was ₹553 Mil.
Total Current Liabilities was ₹4,702 Mil.
Long-Term Debt & Capital Lease Obligation was ₹510 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(10729.64 / 25518.32) / (10096.06 / 23868.84)
=0.420468 / 0.422981
=0.9941

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(13060.32 / 23868.84) / (14852.64 / 25518.32)
=0.54717 / 0.582038
=0.9401

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (26493.6 + 12913.77) / 39828.97) / (1 - (23351.58 + 10457.23) / 34114.53)
=0.010585 / 0.008962
=1.1811

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=25518.32 / 23868.84
=1.0691

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(606.09 / (606.09 + 10457.23)) / (753.57 / (753.57 + 12913.77))
=0.054784 / 0.055137
=0.9936

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 25518.32) / (552.84 / 23868.84)
=0 / 0.023162
=0

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((487.94 + 5080.35) / 39828.97) / ((509.58 + 4701.59) / 34114.53)
=0.139805 / 0.152755
=0.9152

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(5644.83 - 0 - 5654.13) / 39828.97
=-0.000233

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Alivus Life Sciences has a M-score of -2.18 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.18 mean?
Alivus Life Sciences (NSE:ALIVUS) has a Beneish M-Score of -2.18 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Alivus Life Sciences and its competitors. According to the industry distribution chart, Alivus Life Sciences ranks #650 out of 911 companies in the Drug Manufacturers industry, placing it in the top 71.4%.
Is Alivus Life Sciences' Beneish M-Score too high?
Alivus Life Sciences' current Beneish M-Score is -2.18. Based on the distribution chart, Alivus Life Sciences ranks #650 out of 911 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Alivus Life Sciences has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Alivus Life Sciences' Beneish M-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Alivus Life Sciences ranks #650 out of 911 companies for Beneish M-Score. This places Alivus Life Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Alivus Life Sciences and its competitors. Alivus Life Sciences's current Beneish M-Score is -2.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alivus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Alivus Life Sciences (NSE:ALIVUS) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,004.54, compared to a current price of ₹1,108.30 — trading 10.3% above its estimated fair value. The current Beneish M-Score is -2.18. Alivus Life Sciences' overall GF Score™ is 83/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Alivus Life Sciences (NSE:ALIVUS), the current Beneish M-Score is -2.18 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alivus Life Sciences (NSE:ALIVUS) Overvalued in 2026?

Based on GuruFocus' analysis, Alivus Life Sciences stock appears to be overvalued. The current stock price of ₹1,108.30 is trading 10.3% above its estimated GF Value™ of ₹1,004.54. GuruFocus considers Alivus Life Sciences to be Fairly Valued.

Key valuation signals for NSE:ALIVUS:

  • Beneish M-Score: -2.18
  • GF Value™: ₹1,004.54 vs. price of ₹1,108.30 (10.3% above fair value)
  • GF Score™: 83/100 with 3 warning signs

No single metric tells the full story. See the NSE:ALIVUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Alivus Life Sciences Business Description

Other Exchanges 543322:India
Address 470, Cardinal Gracious Road, 4th Floor, OIA House, Andheri (East), Mumbai, MH, IND, 400 099
Alivus Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disorders, pain management, diabetes, urology, gastrointestinal disorders, and other therapeutic areas.
83GF Score

Get the complete analysis for NSE:ALIVUS

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,108.30
Price
₹1,004.54
GF Value